Johnson & Johnson· @JNJNews · X·· 2025-11-06精选AI 评分72
AI 导读
强生宣布，美国FDA批准其一款疗法作为成人重度抑郁症（MDD）的辅助治疗。该批准面向在使用抗抑郁药治疗后仍存在残留症状的患者，强生称这类患者约占三分之二。更多信息见 https://social.jnj.com/4965svt。
推荐理由
强生披露其疗法获FDA批准作为重度抑郁症辅助治疗，并给出适用人群的残留症状比例。
正文
Today, the U.S. FDA approved one of our therapies as an adjunctive treatment for adults living with major depressive disorder (MDD) – offering hope to the 2 in 3 patients who experience residual symptoms despite their antidepressant treatment. Learn more here: https://social.jnj.com/4965svt
来源：Johnson & Johnson · x.com